Digestive diseases and sciences · 2026
Pneumococcal Vaccine Is Associated with Improved Outcomes in Inflammatory Bowel Disease: Insights from a Propensity-Matched Study in the United States.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mohamed Mouhand F H, Gupta Sapana R, Beran Azizullah, Hamid Osama, Farraye Francis A, Shah Samir A
Аннотация
INTRODUCTION: Patients with inflammatory bowel disease (IBD) are at higher risk of pneumonia due to the disease itself and the use of immune-modifying medications.
METHODS: We conducted a retrospective analysis of TriNetX US Collaborative Network data on patients with IBD who received the 20-valent pneumococcal conjugate vaccine (PCV20). Propensity score matching was performed to adjust for differences in demographics and pneumonia-related risk factors.
RESULTS: After propensity score matching, 12,796 patients were included in the analysis. The mean ages of the vaccinated and control groups were 55.2 ± 16.3 and 55.8 ± 17.1 years, respectively, with females comprising 53% of each group. The most commonly prescribed IBD therapies across both cohorts included prednisone, methylprednisolone, budesonide, and adalimumab. Compared to the control group, patients who received PCV20 experienced significantly lower risks of pneumonia, acute respiratory failure, hospital admissions, ICU admissions, and all-cause mortality.
DISCUSSION: These findings align with current recommendations supporting pneumococcal vaccination in adult patients with IBD and highlight the importance of further studies to clarify the extent of vaccine-related benefit in this population.
METHODS: We conducted a retrospective analysis of TriNetX US Collaborative Network data on patients with IBD who received the 20-valent pneumococcal conjugate vaccine (PCV20). Propensity score matching was performed to adjust for differences in demographics and pneumonia-related risk factors.
RESULTS: After propensity score matching, 12,796 patients were included in the analysis. The mean ages of the vaccinated and control groups were 55.2 ± 16.3 and 55.8 ± 17.1 years, respectively, with females comprising 53% of each group. The most commonly prescribed IBD therapies across both cohorts included prednisone, methylprednisolone, budesonide, and adalimumab. Compared to the control group, patients who received PCV20 experienced significantly lower risks of pneumonia, acute respiratory failure, hospital admissions, ICU admissions, and all-cause mortality.
DISCUSSION: These findings align with current recommendations supporting pneumococcal vaccination in adult patients with IBD and highlight the importance of further studies to clarify the extent of vaccine-related benefit in this population.